Gilead Files Single-Pill HCV Therapy In Japan
This article was originally published in PharmAsia News
Executive Summary
Gilead Sciences Inc. has filed for the approval in Japan of what is poised to become the first single-pill regimen in the country for hepatitis C, a major public health problem.